Two independent clinical trials are showing that patients with HIV and latent tuberculosis infections may only need two months of treatment to prevent active tuberculosis development. Studies examined the use of rifampin (RIF) and pyrazinamide (PZA), or isoniazid (INH) and pyridoxine. Results show that RIF/PZA, dosed either daily or twice weekly, is as effective in preventing tuberculosis in dually-infected adults, as INH/pyridoxine given for 6-12 months. Data on drug regimens used in preventing tuberculosis in patients with HIV infection are highlighted.
|Original language||English (US)|
|Number of pages||2|
|Journal||The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service|
|State||Published - May 1998|
ASJC Scopus subject areas